<DOC>
	<DOC>NCT03024424</DOC>
	<brief_summary>The goals of this study are: To assess the impact of genetic testing based on how it alters behaviors, to assess the utility of serum biomarker measurement in combination with genetic testing, to assess the utility of genetic counseling in personal analysis of risk for age-related macular degeneration (AMD), and to assess the impact of presymptomatic genetic testing for choroidal neovascularization (CNV).</brief_summary>
	<brief_title>Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<criteria>Caucasian (this particular genetic test is only validated in Caucasians) Participants can have a positive family history of AMD but this is not necessary. Individuals with a personal history of AMD are not eligible. Noncaucasian individuals are not eligible. Employees of the Moran Eye Center are not eligible.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>